Market Research Logo

Ionis Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Ionis Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Ionis Pharmaceuticals, Inc. - Product Pipeline Review - 2016’, provides an overview of the Ionis Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Ionis Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Ionis Pharmaceuticals, Inc.
  • The report provides overview of Ionis Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Ionis Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Ionis Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Ionis Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Ionis Pharmaceuticals, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Ionis Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Ionis Pharmaceuticals, Inc. Snapshot
Ionis Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Ionis Pharmaceuticals, Inc. - Research and Development Overview
Key Therapeutic Areas
Ionis Pharmaceuticals, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
Ionis Pharmaceuticals, Inc. - Pipeline Products Glance
Ionis Pharmaceuticals, Inc. - Late Stage Pipeline Products
Phase III Products/Combination Treatment Modalities
Ionis Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Ionis Pharmaceuticals, Inc. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Ionis Pharmaceuticals, Inc. - Drug Profiles
nusinersen
Product Description
Mechanism of Action
R&D Progress
IONIS-463588
Product Description
Mechanism of Action
R&D Progress
IONIS-FXIRx
Product Description
Mechanism of Action
R&D Progress
IONIS-GCCRRx
Product Description
Mechanism of Action
R&D Progress
IONIS-GCGRRx
Product Description
Mechanism of Action
R&D Progress
IONIS-PTP1BRx
Product Description
Mechanism of Action
R&D Progress
ISIS-CRPRx
Product Description
Mechanism of Action
R&D Progress
IONIS-APOALRx
Product Description
Mechanism of Action
R&D Progress
IONIS-HTTRx
Product Description
Mechanism of Action
R&D Progress
IONISDMPK-2.5Rx
Product Description
Mechanism of Action
R&D Progress
ISIS-EIF4ERx
Product Description
Mechanism of Action
R&D Progress
ISIS-SOD1Rx
Product Description
Mechanism of Action
R&D Progress
IONIS-DGAT2Rx
Product Description
Mechanism of Action
R&D Progress
IONIS-HBV-LRx
Product Description
Mechanism of Action
R&D Progress
IONIS-HBVRx
Product Description
Mechanism of Action
R&D Progress
IONIS-PKKRx
Product Description
Mechanism of Action
R&D Progress
IONISGSK-4LRx
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotide to Inhibit C9ORF72 Protein for Amyotrophic Lateral Sclerosis
Product Description
Mechanism of Action
R&D Progress
IONIS-AGTLRx
Product Description
Mechanism of Action
R&D Progress
IONIS-TMPRSS6LRx
Product Description
Mechanism of Action
R&D Progress
IONISBIIB-4Rx
Product Description
Mechanism of Action
R&D Progress
IONISBIIB-5Rx
Product Description
Mechanism of Action
R&D Progress
IONISBIIB-6Rx
Product Description
Mechanism of Action
R&D Progress
ISIS-AATRx
Product Description
Mechanism of Action
R&D Progress
ISIS-FVIIRx
Product Description
Mechanism of Action
R&D Progress
ISIS-GHRLRx
Product Description
Mechanism of Action
R&D Progress
ISIS-RHO2.5Rx
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotides to Inhibit BCL11A and KLF1 for Hematological Disorders
Product Description
Mechanism of Action
R&D Progress
Ionis Pharmaceuticals, Inc. - Pipeline Analysis
Ionis Pharmaceuticals, Inc. - Pipeline Products by Target
Ionis Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
Ionis Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
Ionis Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
Ionis Pharmaceuticals, Inc. - Recent Pipeline Updates
Ionis Pharmaceuticals, Inc. - Dormant Projects
Ionis Pharmaceuticals, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
ISIS-104838
ISIS-113715
ISIS-14803
ISIS-2503
ISIS-5132
ISIS-CRPRx
ISIS-EIF4ERx
Ionis Pharmaceuticals, Inc. - Company Statement
Ionis Pharmaceuticals, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Ionis Pharmaceuticals, Inc., Key Information
Ionis Pharmaceuticals, Inc., Key Facts
Ionis Pharmaceuticals, Inc. - Pipeline by Indication, 2016
Ionis Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
Ionis Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
Ionis Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016
Ionis Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2016
Ionis Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2016
Ionis Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
Ionis Pharmaceuticals, Inc. - Phase III, 2016
Ionis Pharmaceuticals, Inc. - Phase II, 2016
Ionis Pharmaceuticals, Inc. - Phase I, 2016
Ionis Pharmaceuticals, Inc. - Preclinical, 2016
Ionis Pharmaceuticals, Inc. - Discovery, 2016
Ionis Pharmaceuticals, Inc. - Pipeline by Target, 2016
Ionis Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
Ionis Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
Ionis Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
Ionis Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016
Ionis Pharmaceuticals, Inc. - Dormant Developmental Projects,2016
Ionis Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016
Ionis Pharmaceuticals, Inc., Subsidiaries
List of Figures
Ionis Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016
Ionis Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
Ionis Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
Ionis Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016
Ionis Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2016
Ionis Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2016
Ionis Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
Ionis Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
Ionis Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report